Engineered zwitterion-nanodelivery for precision targeting of brain metastases.

Authors

Haibao Peng, Youming Zeng, Yang Huang, Chenyu Lin, Zeyu Lei, Peixin Sun, Jiahui Yang, Shaoqi Sheng, Yuxin Huang, Xiaohui Li, Jiaxu Zhao, Rui Zeng, Cheng Li, Wanqi Yang, Xiangjie Di, Sisi He, Yongsheng Wang, Hanting Yang, Wuli Yang, Yudan Chi

Published in

Nature communications. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

The central nervous system is a critical reservoir for cancer metastasis, underscoring the urgent need for effective strategies for targeted drug delivery that minimize systemic side effects. Here, we present a zwitterionic polycarboxybetaine (PCB) designed to achieve selective accumulation within the tumor vasculature of brain metastases, thereby facilitating the rapid release of therapeutics without relying on external stimuli in preclinical models. PCB selectively targets the betaine-γ-aminobutyric acid transporter 1 (BGT1) at the blood-brain-tumor barrier (BBTB), enabling localized enrichment of nanoparticles within the tumor vasculature. The intrinsic mechanical flexibility of PCB activates the Piezo1 ion channel in endothelial cells, resulting in calcium ion influx and enhanced calpain activity, which together facilitate the degradation of VE-cadherin. The burst-release mechanism improves vascular permeability and compromises the integrity of the tumor vascular barrier, allowing for the swift release of encapsulated therapeutics and promoting extensive drug distribution within the tumor microenvironment. Notably, PCB encapsulating either osimertinib or cisplatin demonstrates therapeutic efficacy, intratumoral targeting, and favorable biological safety in disease models. These findings indicate that this zwitterion-functionalized platform effectively surmounts the challenges posed by the BBTB, supporting improved drug delivery and therapeutic efficacy in brain metastases.

PMID:
42425968
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.